Mab-Venture Biopharm

Mabwell is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic antibodies and antibody-drug conjugates (ADCs). The company operates a fully integrated platform covering the entire drug development lifecycle, from target discovery to commercial-scale manufacturing. Its pipeline includes several late-stage candidates and approved biosimilars targeting oncology, autoimmune, and metabolic conditions. Mabwell is notably advanced in the ADC space, with its Nectin-4 targeting ADC (9MW2821) showing significant clinical promise in urothelial and cervical cancers. The company is listed on the Shanghai STAR Market and maintains a global presence through strategic partnerships and clinical trials.